Risperidone-induced cholestatic hepatitis.
Risperidone, a widely used atypical and potent neuroleptic drug, is assumed to induce fewer hepatic side-effects than phenothiazine anti-psychotics. Recently, we observed a case of risperidone-induced cholestatic hepatotoxicity. A 37-year-old male developed a rapid increase in liver enzymes and cholestatic parameters after starting treatment with risperidone for paranoid psychosis. Work-up for other potential aetiologies was negative. The results of a percutaneous liver biopsy were consistent with drug-induced liver injury and cholestasis. Over the course of one month after the discontinuance of all anti-psychotic agents, the liver function test results returned to near-normal values. This observation supports the need to monitor cholestatic parameters in addition to liver function enzymes during initiation and the first weeks of risperidone intake.
Krebs
S
S
Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-University Erlangen-Nuremberg, Germany. krebs@pharmakologie.uni-erlangen.de
Dormann
H
H
Muth-Selbach
U
U
Hahn
E G
EG
Brune
K
K
Schneider
H T
HT
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology*; D002779:Cholestasis / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008099:Liver / Q000187:drug effects; D008111:Liver Function Tests; D008297:Male; D018967:Risperidone / Q000009:adverse effects*
D014150:Antipsychotic Agents; D018967:Risperidone